Peptide Drug Conjugates Market Size, Share & Trends Analysis Report By Product (Lutetium, Melflufen, ANG1005, BT1718, CBX-12, Other Pipeline), By Type (Diagnostic, Therapeutic), By Region, And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within 3 Business Days
Peptide Drug Conjugates Market Growth & Trends
The global peptide drug conjugates market is expected to reach USD 2.67 billion by 2030, registering CAGR of 18.58% during the forecast period, according to a new report by Grand View Research, Inc. The growth of market is attributed to the global upsurge in cancer cases and related mortality, strong clinical trial pipeline with peptide drug conjugates (PDCs) and associated side effects of the existing products such as uncontrolled toxicity associated with small molecule chemotherapeutic agents.
According to WHO, cancer is the leading cause of disease related deaths, worldwide. In 2020, around 10.0 million deaths globally and more than 6.0 million deaths in the U.S. were recorded due to the cancer. Furthermore, as per cancer.gov, by 2040, the new cancer cases patients per year is estimated to reach to 29.0 million and the number of cancer-related deaths to 16.0 million. Therefore, rising demand for the novel treatment like PDCs to target uncontrolled cell growth is expected to fuel the peptide drug conjugates market growth.
Currently, Lutathera (Lu 177 dotatate) and Pepaxto (Melflufen) are the two FDA approved PDCs to treat uncontrolled cell growth. The marketplace has the FDA approved PDC as the Novartis’s Lutathera (lutetium Lu 177)indicated for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults. Later, in February 2021, Oncopeptides ABs announced the FDA’s accelerated approval for Pepaxto (Melphalan) indicated for the treatment in multiple myeloma. Presence of limited PDCs in space in offering remunerative opportunity for the growth.
Furthermore, presence of robust clinical trial pipeline and expected launch of new PDCs is anticipated to boost the market growth during the forecast period. These can attribute due to the PDC ANG1005 under phase 3 clinical studies for brain tumor, and PDCs BT5528 and BT1718 under phase 2 to clinical studies for lung cancer. CBX-12 is another phase 2 PDC candidate indicated for the small cell lung cancer treatment.
Key players are undertaking strategic initiatives such as collaborations, merger & acquisitions, agreements, along with financial investments, which is driving the market growth. For instance, in December 2021, Coherent Biopharma and WuXi STA announced the strategic partnership agreement to develop their current and future therapeutic drugs including peptide drug conjugates.
Peptide Drug Conjugates Market Report Highlights
Peptide Drug Conjugates Market Growth & Trends
The global peptide drug conjugates market is expected to reach USD 2.67 billion by 2030, registering CAGR of 18.58% during the forecast period, according to a new report by Grand View Research, Inc. The growth of market is attributed to the global upsurge in cancer cases and related mortality, strong clinical trial pipeline with peptide drug conjugates (PDCs) and associated side effects of the existing products such as uncontrolled toxicity associated with small molecule chemotherapeutic agents.
According to WHO, cancer is the leading cause of disease related deaths, worldwide. In 2020, around 10.0 million deaths globally and more than 6.0 million deaths in the U.S. were recorded due to the cancer. Furthermore, as per cancer.gov, by 2040, the new cancer cases patients per year is estimated to reach to 29.0 million and the number of cancer-related deaths to 16.0 million. Therefore, rising demand for the novel treatment like PDCs to target uncontrolled cell growth is expected to fuel the peptide drug conjugates market growth.
Currently, Lutathera (Lu 177 dotatate) and Pepaxto (Melflufen) are the two FDA approved PDCs to treat uncontrolled cell growth. The marketplace has the FDA approved PDC as the Novartis’s Lutathera (lutetium Lu 177)indicated for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults. Later, in February 2021, Oncopeptides ABs announced the FDA’s accelerated approval for Pepaxto (Melphalan) indicated for the treatment in multiple myeloma. Presence of limited PDCs in space in offering remunerative opportunity for the growth.
Furthermore, presence of robust clinical trial pipeline and expected launch of new PDCs is anticipated to boost the market growth during the forecast period. These can attribute due to the PDC ANG1005 under phase 3 clinical studies for brain tumor, and PDCs BT5528 and BT1718 under phase 2 to clinical studies for lung cancer. CBX-12 is another phase 2 PDC candidate indicated for the small cell lung cancer treatment.
Key players are undertaking strategic initiatives such as collaborations, merger & acquisitions, agreements, along with financial investments, which is driving the market growth. For instance, in December 2021, Coherent Biopharma and WuXi STA announced the strategic partnership agreement to develop their current and future therapeutic drugs including peptide drug conjugates.
Peptide Drug Conjugates Market Report Highlights
- By product, Lutathera segment accounted for the largest share of the market in 2021 due to the first approved PDC and global rise in cancer patients which is offering high demand for these medicines
- Based on type, the therapeutic segment dominated the peptide drug conjugates market in 2021 owing to the presence of both approved PDCs, Lutathera and Pepaxto as therapeutic agents targeting tumor cells
- North America dominated the global market in 2021 owing to the factors such as an increase in new cancer cases along with related complexity and high awareness among healthcare professionals about novel therapies
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation and Scope
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation and Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective
1.10.2 Objective
1.10.3 Objective
1.10.4 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Snapshot
CHAPTER 3 PEPTIDE DRUG CONJUGATES: MARKET VARIABLES, TRENDS, AND SCOPE
3.1 Market Lineage Outlook
3.2 Penetration and Growth Prospect Mapping
3.3 Regulatory Landscape
3.4 Market Dynamics
3.5 Market Driver Analysis
3.5.1.1 Rising Cancer Cases and Related Mortality
3.5.1.2 Robust Clinical Trial Pipeline
3.6 Market Restraint Analysis
3.6.1.1 Long R&D Time and Slow Clinical Development Process
3.7 PESTEL Analysis
3.8 Industry Analysis - Porter’s Five Forces
3.9 Pipeline Analysis
CHAPTER 4 PEPTIDE DRUG CONJUGATES MARKET: SEGMENT ANALYSIS, BY PRODUCT, 2018 - 2030 (USD MILLION)
4.1 Peptide Drug Conjugates Market: Product Movement Analysis
4.2 Lutetium
4.2.1 Lutetium Market, 2018 - 2030 (USD Million)
4.3 Melflufen
4.3.1 Melflufen Market, 2018 - 2030 (USD Million)
4.4 ANG1005
4.4.1 ANG1005 Market, 2018 - 2030 (USD Million)
4.5 BT1718
4.5.1 BT1718 Market, 2018 - 2030 (USD Million)
4.6 CBX-12
4.6.1 CBX-12 Market, 2018 - 2030 (USD Million)
4.7 Other Pipeline Products
4.7.1 Other Pipeline ProductsMarket, 2018 - 2030 (USD Million)
CHAPTER 5 PEPTIDE DRUG CONJUGATES MARKET: SEGMENT ANALYSIS, BY TYPE, 2018 - 2030 (USD MILLION)
5.1 Peptide Drug Conjugates Market: Type Movement Analysis
5.2 Therapeutic
5.2.1 TherapeuticMarket, 2018 - 2030 (USD Million)
5.3 Diagnostic
5.3.1 Diagnostic Market, 2018 - 2030 (USD Million)
CHAPTER 6 PEPTIDE DRUG CONJUGATES MARKET: SEGMENT ANALYSIS, BY REGION, 2018 - 2030 (USD MILLION)
6.1 Regional Market Snapshot
6.2 Regional Market Share Analysis, 2021 & 2030
6.3 Market Size, Forecasts, and Revenue & Trend Analysis, 2021 to 2030
6.3.1 North America
6.3.1.1 North America Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.1.2 U.S.
6.3.1.2.1 U.S. Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.1.3 Canada
6.3.1.3.1 Canada Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.2 Europe
6.3.2.1 Europe Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.2.2 UK
6.3.2.2.1 UK Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.2.3 Germany
6.3.2.3.1 Germany Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.2.4 Spain
6.3.2.4.1 Spain Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.2.5 France
6.3.2.5.1 France Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.2.6 Italy
6.3.2.6.1 Italy Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.3 Asia Pacific
6.3.3.1 Asia Pacific Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.3.2 Japan
6.3.3.2.1 Japan Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.3.3 China
6.3.3.3.1 China Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.3.4 India
6.3.3.4.1 India Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.3.5 Australia
6.3.3.5.1 Australia Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.3.6 South Korea
6.3.3.6.1 South Korea Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.4 Latin America
6.3.4.1 Latin America Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.4.2 Brazil
6.3.4.2.1 Brazil Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.4.3 Mexico
6.3.4.3.1 Mexico Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.4.4 Argentina
6.3.4.4.1 Argentina Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.5 MEA
6.3.5.1 MEA Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.5.2 South Africa
6.3.5.2.1 South Africa Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.5.3 Saudi Arabia
6.3.5.3.1 Saudi Arabia Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.5.4 UAE
6.3.5.4.1 UAE Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
CHAPTER 7 PEPTIDE DRUG CONJUGATES MARKET: COMPETITIVE ANALYSIS
7.1 Strategic Initiatives and Impact Analysis, by Key Market Participants
7.1.1 Synergy Analysis: Major Deals and Strategic Alliances
7.1.1.1 New Product Launches
7.1.1.2 Mergers and Acquisitions
7.1.1.3 Licensing Agreements
7.2 Company Categorization
7.2.1 Innovators
7.2.2 Market Leaders
7.2.3 Emerging Players
7.2.4 Heat Map Analysis
7.3 Company Market Position Analysis
7.4 Vendor Landscape
7.4.1 List of Key Distributors and Channel Partners
7.4.2 List of Potential End-Users
7.4.3 Key Company Market Share Analysis, 2021
7.4.4 Consumer Behavior Analysis
7.4.5 Competitive Dashboard Analysis
7.5 Private Companies
7.5.1 List of Key Emerging Companies
7.5.2 Regional Network Map
7.6 Company Profiles
7.6.1 Novartis AG.
7.6.1.1 Company Overview
7.6.1.2 Financial Performance
7.6.1.3 Product Benchmarking
7.6.1.4 Strategic Initiatives
7.6.2 Bicycle Therapeutics
7.6.2.1 Company Overview
7.6.2.2 Financial Performance
7.6.2.3 Product Benchmarking
7.6.2.4 Strategic Initiatives
7.6.3 AstraZeneca
7.6.3.1 Company Overview
7.6.3.2 Financial Performance
7.6.3.3 Product Benchmarking
7.6.3.4 Strategic Initiatives
7.6.4 Cybrexa Therapeutics
7.6.4.1 Company Overview
7.6.4.2 Financial Performance
7.6.4.3 Product Benchmarking
7.6.4.4 Strategic Initiatives
7.6.5 Oncopeptides Inc.
7.6.5.1 Company Overview
7.6.5.2 Financial Performance
7.6.5.3 Product Benchmarking
7.6.5.4 Strategic Initiatives
7.6.6 Angiochem Inc.
7.6.6.1 Company Overview
7.6.6.2 Financial Performance
7.6.6.3 Product Benchmarking
7.6.7 Innovasium Soricimed Biopharma
7.6.7.1 Company Overview
7.6.7.2 Financial performance
7.6.7.3 Product Benchmarking
7.6.7.4 Strategic Initiatives
7.6.8 Theratechnologies
7.6.8.1 Company Overview
7.6.8.2 Financial performance
7.6.8.3 Product Benchmarking
7.6.8.4 Strategic Initiatives
1.1 Market Segmentation and Scope
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation and Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective
1.10.2 Objective
1.10.3 Objective
1.10.4 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Snapshot
CHAPTER 3 PEPTIDE DRUG CONJUGATES: MARKET VARIABLES, TRENDS, AND SCOPE
3.1 Market Lineage Outlook
3.2 Penetration and Growth Prospect Mapping
3.3 Regulatory Landscape
3.4 Market Dynamics
3.5 Market Driver Analysis
3.5.1.1 Rising Cancer Cases and Related Mortality
3.5.1.2 Robust Clinical Trial Pipeline
3.6 Market Restraint Analysis
3.6.1.1 Long R&D Time and Slow Clinical Development Process
3.7 PESTEL Analysis
3.8 Industry Analysis - Porter’s Five Forces
3.9 Pipeline Analysis
CHAPTER 4 PEPTIDE DRUG CONJUGATES MARKET: SEGMENT ANALYSIS, BY PRODUCT, 2018 - 2030 (USD MILLION)
4.1 Peptide Drug Conjugates Market: Product Movement Analysis
4.2 Lutetium
4.2.1 Lutetium Market, 2018 - 2030 (USD Million)
4.3 Melflufen
4.3.1 Melflufen Market, 2018 - 2030 (USD Million)
4.4 ANG1005
4.4.1 ANG1005 Market, 2018 - 2030 (USD Million)
4.5 BT1718
4.5.1 BT1718 Market, 2018 - 2030 (USD Million)
4.6 CBX-12
4.6.1 CBX-12 Market, 2018 - 2030 (USD Million)
4.7 Other Pipeline Products
4.7.1 Other Pipeline ProductsMarket, 2018 - 2030 (USD Million)
CHAPTER 5 PEPTIDE DRUG CONJUGATES MARKET: SEGMENT ANALYSIS, BY TYPE, 2018 - 2030 (USD MILLION)
5.1 Peptide Drug Conjugates Market: Type Movement Analysis
5.2 Therapeutic
5.2.1 TherapeuticMarket, 2018 - 2030 (USD Million)
5.3 Diagnostic
5.3.1 Diagnostic Market, 2018 - 2030 (USD Million)
CHAPTER 6 PEPTIDE DRUG CONJUGATES MARKET: SEGMENT ANALYSIS, BY REGION, 2018 - 2030 (USD MILLION)
6.1 Regional Market Snapshot
6.2 Regional Market Share Analysis, 2021 & 2030
6.3 Market Size, Forecasts, and Revenue & Trend Analysis, 2021 to 2030
6.3.1 North America
6.3.1.1 North America Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.1.2 U.S.
6.3.1.2.1 U.S. Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.1.3 Canada
6.3.1.3.1 Canada Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.2 Europe
6.3.2.1 Europe Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.2.2 UK
6.3.2.2.1 UK Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.2.3 Germany
6.3.2.3.1 Germany Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.2.4 Spain
6.3.2.4.1 Spain Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.2.5 France
6.3.2.5.1 France Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.2.6 Italy
6.3.2.6.1 Italy Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.3 Asia Pacific
6.3.3.1 Asia Pacific Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.3.2 Japan
6.3.3.2.1 Japan Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.3.3 China
6.3.3.3.1 China Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.3.4 India
6.3.3.4.1 India Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.3.5 Australia
6.3.3.5.1 Australia Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.3.6 South Korea
6.3.3.6.1 South Korea Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.4 Latin America
6.3.4.1 Latin America Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.4.2 Brazil
6.3.4.2.1 Brazil Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.4.3 Mexico
6.3.4.3.1 Mexico Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.4.4 Argentina
6.3.4.4.1 Argentina Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.5 MEA
6.3.5.1 MEA Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.5.2 South Africa
6.3.5.2.1 South Africa Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.5.3 Saudi Arabia
6.3.5.3.1 Saudi Arabia Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3.5.4 UAE
6.3.5.4.1 UAE Peptide Drug Conjugates Market Estimates and Forecast, 2018 - 2030 (USD Million)
CHAPTER 7 PEPTIDE DRUG CONJUGATES MARKET: COMPETITIVE ANALYSIS
7.1 Strategic Initiatives and Impact Analysis, by Key Market Participants
7.1.1 Synergy Analysis: Major Deals and Strategic Alliances
7.1.1.1 New Product Launches
7.1.1.2 Mergers and Acquisitions
7.1.1.3 Licensing Agreements
7.2 Company Categorization
7.2.1 Innovators
7.2.2 Market Leaders
7.2.3 Emerging Players
7.2.4 Heat Map Analysis
7.3 Company Market Position Analysis
7.4 Vendor Landscape
7.4.1 List of Key Distributors and Channel Partners
7.4.2 List of Potential End-Users
7.4.3 Key Company Market Share Analysis, 2021
7.4.4 Consumer Behavior Analysis
7.4.5 Competitive Dashboard Analysis
7.5 Private Companies
7.5.1 List of Key Emerging Companies
7.5.2 Regional Network Map
7.6 Company Profiles
7.6.1 Novartis AG.
7.6.1.1 Company Overview
7.6.1.2 Financial Performance
7.6.1.3 Product Benchmarking
7.6.1.4 Strategic Initiatives
7.6.2 Bicycle Therapeutics
7.6.2.1 Company Overview
7.6.2.2 Financial Performance
7.6.2.3 Product Benchmarking
7.6.2.4 Strategic Initiatives
7.6.3 AstraZeneca
7.6.3.1 Company Overview
7.6.3.2 Financial Performance
7.6.3.3 Product Benchmarking
7.6.3.4 Strategic Initiatives
7.6.4 Cybrexa Therapeutics
7.6.4.1 Company Overview
7.6.4.2 Financial Performance
7.6.4.3 Product Benchmarking
7.6.4.4 Strategic Initiatives
7.6.5 Oncopeptides Inc.
7.6.5.1 Company Overview
7.6.5.2 Financial Performance
7.6.5.3 Product Benchmarking
7.6.5.4 Strategic Initiatives
7.6.6 Angiochem Inc.
7.6.6.1 Company Overview
7.6.6.2 Financial Performance
7.6.6.3 Product Benchmarking
7.6.7 Innovasium Soricimed Biopharma
7.6.7.1 Company Overview
7.6.7.2 Financial performance
7.6.7.3 Product Benchmarking
7.6.7.4 Strategic Initiatives
7.6.8 Theratechnologies
7.6.8.1 Company Overview
7.6.8.2 Financial performance
7.6.8.3 Product Benchmarking
7.6.8.4 Strategic Initiatives
LIST OF TABLES
Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 List of Parameters
Table 4 List of Distributors
Table 5 Global Peptide Drug Conjugates Market, By Region, 2018 - 2030 (USD Million)
Table 6 Global Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 7 Global Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 8 North America Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
Table 9 North America Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 10 North America Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 11 U.S. Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 12 U.S. Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 13 Canada Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 14 Canada Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 15 Europe Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
Table 16 Europe Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 17 Europe Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 18 Germany Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 19 Germany Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 20 UK Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 21 UK Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 22 France Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 23 France Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 24 Italy Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 25 Italy Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 26 Spain Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 27 Spain Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 28 Asia Pacific Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
Table 29 Asia Pacific Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 30 Asia Pacific Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 31 Japan Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 32 Japan Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 33 China Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 34 China Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 35 India Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 36 India Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 37 South Korea Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 38 South Korea Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 39 Australia Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 40 Australia Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 41 Latin America Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
Table 42 Latin America Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 43 Latin America Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 44 Brazil Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 45 Brazil Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 46 Mexico Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 47 Mexico Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 48 Argentina Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 49 Argentina Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 50 Middle East & Africa Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
Table 51 Middle East & Africa Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 52 Middle East & Africa Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 53 Saudi Arabia Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 54 Saudi Arabia Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 55 South Africa Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 56 South Africa Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 57 UAE Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 58 UAE Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 List of Parameters
Table 4 List of Distributors
Table 5 Global Peptide Drug Conjugates Market, By Region, 2018 - 2030 (USD Million)
Table 6 Global Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 7 Global Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 8 North America Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
Table 9 North America Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 10 North America Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 11 U.S. Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 12 U.S. Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 13 Canada Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 14 Canada Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 15 Europe Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
Table 16 Europe Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 17 Europe Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 18 Germany Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 19 Germany Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 20 UK Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 21 UK Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 22 France Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 23 France Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 24 Italy Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 25 Italy Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 26 Spain Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 27 Spain Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 28 Asia Pacific Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
Table 29 Asia Pacific Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 30 Asia Pacific Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 31 Japan Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 32 Japan Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 33 China Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 34 China Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 35 India Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 36 India Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 37 South Korea Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 38 South Korea Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 39 Australia Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 40 Australia Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 41 Latin America Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
Table 42 Latin America Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 43 Latin America Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 44 Brazil Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 45 Brazil Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 46 Mexico Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 47 Mexico Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 48 Argentina Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 49 Argentina Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 50 Middle East & Africa Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
Table 51 Middle East & Africa Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 52 Middle East & Africa Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 53 Saudi Arabia Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 54 Saudi Arabia Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 55 South Africa Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 56 South Africa Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 57 UAE Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 58 UAE Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Peptide Drug Conjugates (PDC) Market Segmentation
Fig. 2 Market Research Process
Fig. 3 Information Procurement
Fig. 4 Primary Research Pattern
Fig. 5 Market Research Approaches
Fig. 6 Value Chain-Based Sizing & Forecasting
Fig. 7 QFD Modeling for Market Share Assessment
Fig. 8 Market Formulation & Validation
Fig. 9 Commodity Flow Approach
Fig. 10 Market Snapshot (2021) (USD Million)
Fig. 11 Segment Snapshot (2021) (USD Million)
Fig. 12 Competitive Snapshot
Fig. 13 Penetration &Growth Prospect Mapping
Fig. 14 PDCsMarket Driver Impact
Fig. 15 PDCs Market Restraint Impact
Fig. 16 PESTEL Analysis
Fig. 17 Porter’s Five Forces Analysis
Fig. 18 Peptide Drug Conjugates (PDCs) Product Outlook: Key Takeaways
Fig. 19 Peptide Drug Conjugates Market: Product Movement Analysis (USD Million)
Fig. 20 Lutetium Market 2018 - 2030 (USD Million)
Fig. 21 Melflufen Market, 2018 - 2030 (USD Million)
Fig. 22 ANG1005 Market, 2018 - 2030 (USD Million)
Fig. 23 BT1718 Market, 2018 - 2030 (USD Million)
Fig. 24 CBX-12 Market, 2018 - 2030 (USD Million)
Fig. 25 Peptide Drug ConjugatesType Outlook: Key Takeaways
Fig. 26 Peptide Drug Conjugates Market: Type Movement Analysis (USD Million)
Fig. 27 TherapeuticMarket, 2018 - 2030 (USD Million)
Fig. 28 Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 29 Peptide Drug Conjugates Distribution Channel Outlook: Key Takeaways
Fig. 30 Regional Snapshot, 2021 & 2030
Fig. 31 Regional MarketPlace: Key takeaways
Fig. 32 North America
Fig. 33 North America Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD million)
Fig. 34 U.S.
Fig. 35 U.S. Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 36 Canada
Fig. 37 Canada Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD million)
Fig. 38 Europe
Fig. 39 Europe Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 40 UK
Fig. 41 UK Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 42 Germany
Fig. 43 Germany Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 44 Spain
Fig. 45 Spain Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 46 France
Fig. 47 France Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 47 Italy
Fig. 48 Italy Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 49 Asia Pacific
Fig. 50 Asia Pacific Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 51 Japan
Fig. 52 Japan Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 53 China
Fig. 54 China Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 55 India
Fig. 56 India Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 57 Australia
Fig. 58 Australia Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 59 South Korea
Fig. 60 South Korea Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 61 Latin America
Fig. 62 Latin America Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 63 Brazil
Fig. 64 Brazil Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 65 Mexico
Fig. 66 Mexico Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 67 Argentina
Fig. 68 Argentina Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 69 Middle East & Africa
Fig. 70 MEA Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 71 South Africa
Fig. 72 South Africa Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 73 Saudi Arabia
Fig. 74 Saudi Arabia Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 75 UAE
Fig. 76 UAE Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 77 Heat Map Analysis
Fig. 78 Company Market Position Analysis, 2021
Fig. 79 Company Market Position Analysis, 2021
Fig. 80 Company Market Share Analysis (2021)
Fig. 81 Consumer Behavior Analysis
Fig. 82 Market Differentiators
Fig. 1 Peptide Drug Conjugates (PDC) Market Segmentation
Fig. 2 Market Research Process
Fig. 3 Information Procurement
Fig. 4 Primary Research Pattern
Fig. 5 Market Research Approaches
Fig. 6 Value Chain-Based Sizing & Forecasting
Fig. 7 QFD Modeling for Market Share Assessment
Fig. 8 Market Formulation & Validation
Fig. 9 Commodity Flow Approach
Fig. 10 Market Snapshot (2021) (USD Million)
Fig. 11 Segment Snapshot (2021) (USD Million)
Fig. 12 Competitive Snapshot
Fig. 13 Penetration &Growth Prospect Mapping
Fig. 14 PDCsMarket Driver Impact
Fig. 15 PDCs Market Restraint Impact
Fig. 16 PESTEL Analysis
Fig. 17 Porter’s Five Forces Analysis
Fig. 18 Peptide Drug Conjugates (PDCs) Product Outlook: Key Takeaways
Fig. 19 Peptide Drug Conjugates Market: Product Movement Analysis (USD Million)
Fig. 20 Lutetium Market 2018 - 2030 (USD Million)
Fig. 21 Melflufen Market, 2018 - 2030 (USD Million)
Fig. 22 ANG1005 Market, 2018 - 2030 (USD Million)
Fig. 23 BT1718 Market, 2018 - 2030 (USD Million)
Fig. 24 CBX-12 Market, 2018 - 2030 (USD Million)
Fig. 25 Peptide Drug ConjugatesType Outlook: Key Takeaways
Fig. 26 Peptide Drug Conjugates Market: Type Movement Analysis (USD Million)
Fig. 27 TherapeuticMarket, 2018 - 2030 (USD Million)
Fig. 28 Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 29 Peptide Drug Conjugates Distribution Channel Outlook: Key Takeaways
Fig. 30 Regional Snapshot, 2021 & 2030
Fig. 31 Regional MarketPlace: Key takeaways
Fig. 32 North America
Fig. 33 North America Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD million)
Fig. 34 U.S.
Fig. 35 U.S. Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 36 Canada
Fig. 37 Canada Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD million)
Fig. 38 Europe
Fig. 39 Europe Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 40 UK
Fig. 41 UK Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 42 Germany
Fig. 43 Germany Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 44 Spain
Fig. 45 Spain Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 46 France
Fig. 47 France Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 47 Italy
Fig. 48 Italy Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 49 Asia Pacific
Fig. 50 Asia Pacific Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 51 Japan
Fig. 52 Japan Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 53 China
Fig. 54 China Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 55 India
Fig. 56 India Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 57 Australia
Fig. 58 Australia Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 59 South Korea
Fig. 60 South Korea Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 61 Latin America
Fig. 62 Latin America Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 63 Brazil
Fig. 64 Brazil Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 65 Mexico
Fig. 66 Mexico Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 67 Argentina
Fig. 68 Argentina Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 69 Middle East & Africa
Fig. 70 MEA Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 71 South Africa
Fig. 72 South Africa Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 73 Saudi Arabia
Fig. 74 Saudi Arabia Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 75 UAE
Fig. 76 UAE Peptide Drug Conjugates (PDCs) Market, 2018 - 2030 (USD Million)
Fig. 77 Heat Map Analysis
Fig. 78 Company Market Position Analysis, 2021
Fig. 79 Company Market Position Analysis, 2021
Fig. 80 Company Market Share Analysis (2021)
Fig. 81 Consumer Behavior Analysis
Fig. 82 Market Differentiators
